Merck Serono Tops BMI's Pharmaceutical Manufacturing Efficiency Index For Q110

Compared with a selection of other drugmakers, Merck Serono spends the smallest proportion of total sales on manufacturing, according to BMI's Pharmaceutical Manufacturing Efficiency Index (PMEI) for Q110. For every US$1 the Geneva-based firm spent on 'cost of goods sold' in the first quarter of 2010, it generated US$6.39 in revenue, giving it a score of 6.39 on our index system. This is an interesting finding because Merck Serono's two leading products - Rebif (interferon beta-1a ) and Erbitux (cetuximab) - are biologics.

To read the full article, please choose one of the following options: